title: The long march to surrogates of meaningful clinical outcomes in MS trials: are we there yet?
authors.forename: J S
authors.initials: JS
authors.lastname: Wolinsky
authors.forename: C A
authors.initials: CA
authors.lastname: Beck
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D004185:Disability Evaluation; D018450:Disease Progression; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000473:pathology* / Q000517:prevention & control*
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a